Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 1. Detection of circulating tumor DNA in CRPC patients.

Published byἭβη Βενιζέλος Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 1. Detection of circulating tumor DNA in CRPC patients."— Presentation transcript:

1 Fig. 1. Detection of circulating tumor DNA in CRPC patients.
Detection of circulating tumor DNA in CRPC patients. (A) Study profile showing the number of patients and samples with next-generation sequencing data and with a circulating tumor DNA fraction ≥ Twenty-six patients (*) and one patient (†) had pre-abiraterone samples only. (B) Correlation of circulating tumor DNA fraction with serum LDH, serum ALP, and AR copy number. Alessandro Romanel et al., Sci Transl Med 2015;7:312re10 Copyright © 2015, American Association for the Advancement of Science

Download ppt "Fig. 1. Detection of circulating tumor DNA in CRPC patients."

Similar presentations

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.
Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.

Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.
AR signaling in CTCs from CRPC patients treated with abiraterone acetate. AR signaling in CTCs from CRPC patients treated with abiraterone acetate. A,

AR signaling in CTCs from CRPC patients treated with abiraterone acetate. AR signaling in CTCs from CRPC patients treated with abiraterone acetate. A,
Degradation of MSP samples in 37°C DPBS solution.

Degradation of MSP samples in 37°C DPBS solution.
Fig. 1. Experimental workflow of the dAST method and computationally estimated operational space. Experimental workflow of the dAST method and computationally.

Fig. 1. Experimental workflow of the dAST method and computationally estimated operational space. Experimental workflow of the dAST method and computationally.
Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.
Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.
Fig. 7 Correlation of NHP and human ISGs.

Fig. 7 Correlation of NHP and human ISGs.
Fig. 1 Movement percepts for all participants.

Fig. 1 Movement percepts for all participants.
Fig. 5 Correlation of RNA expression and protein abundance.

Fig. 5 Correlation of RNA expression and protein abundance.
Fig. 3. The effect of VRC01 infusion on virus load in plasma and blood CD4 T cells during ART. The effect of VRC01 infusion on virus load in plasma and.

Fig. 3. The effect of VRC01 infusion on virus load in plasma and blood CD4 T cells during ART. The effect of VRC01 infusion on virus load in plasma and.
Consolidated Standards of Reporting Trials flow diagram of VRC trial

Consolidated Standards of Reporting Trials flow diagram of VRC trial
Fig. 2 Whisker deprivation accelerates and enhances behavioral recovery after right S1FP photothrombosis. Whisker deprivation accelerates and enhances.

Fig. 2 Whisker deprivation accelerates and enhances behavioral recovery after right S1FP photothrombosis. Whisker deprivation accelerates and enhances.
Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.
Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.

Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.
Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.
Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.

Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.
Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.

Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.
Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.

Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.
Fig. 1. Iontophoretic devices used for the delivery of cytotoxic agents to solid tumors. Iontophoretic devices used for the delivery of cytotoxic agents.

Fig. 1. Iontophoretic devices used for the delivery of cytotoxic agents to solid tumors. Iontophoretic devices used for the delivery of cytotoxic agents.

Similar presentations

Ads by Google